Lastly, weak evidence suggested that KD use may reduce the odds ratio of definite responder rate in CDKL5-related epilepsy (pooled OR: 0.225; p-random effects: 0.012) [74] and may reduce the RR of ≥50% seizure reduction: children (pooled RR: 5.641; p-random effects: <0.001) in Drug-resistant epilepsy [68] (Supplemental Table S3). The gene discussed is CDKL5; the disease is epilepsy.